Skye Bioscience, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Convertible Debt - Related Party (Tables)

Convertible Debt - Related Party (Tables)

3 Months Ended

Mar. 31, 2020

Debt Disclosure [Abstract]

Schedule of convertible debt

		As of March 31, 2020				As of December 31, 2019
Total principal value		$	2,014,500			$	2,014,500
Unamortized debt discount			(1,491,997	)			(1,622,344	)
Unamortized debt issuance costs			(4,723	)			(5,086	)
Carrying value of total convertible debt - related party		$	517,780			$	387,070
Less, noncurrent portion			(517,780	)			(387,070	)
Current convertible debt - related party		$	—			$	—

Schedule of interest expense

		Three Months Ended March 31,
		2020				2019
Interest expense - stated rate		$	35,645			$	59,111
Non-cash interest expense:
Amortization of debt discount			130,347				53,979
Amortization of transaction costs			363				2,973
		$	166,355			$	116,063